<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Pegvisomant</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Pegvisomant">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Pegvisomant</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Pegvisomant</b> (trade name <b>Somavert</b>) is a growth hormone receptor antagonist used in the treatment of acromegaly.<span class="mw-ref" id="cite_ref-Schreiber_1-0"><a href="#cite_note-Schreiber-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy.<span class="mw-ref" id="cite_ref-ReferenceA_2-0"><a href="#cite_note-ReferenceA-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is delivered as a powder that is mixed with water and injected under the skin.<span class="mw-ref" id="cite_ref-ema_3-0"><a href="#cite_note-ema-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Pegvisomant</span></caption><tbody><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Somavert</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/pegvisomant.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/pegvisomant.html'" tppabs="https://www.drugs.com/monograph/pegvisomant.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Pegvisomant  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Pegvisomant'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Pegvisomant" class="external text external">by INN</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>H01AX01<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=H01AX01  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=H01AX01'" tppabs="https://www.whocc.no/atc_ddd_index/?code=H01AX01" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=218620-50-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=218620-50-9'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=218620-50-9" class="external text external">218620-50-9</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7485  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7485'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7485" class="external text external">7485</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00082  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00082'" tppabs="https://www.drugbank.ca/drugs/DB00082" class="external text external">DB00082</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=N824AOU5XV  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=N824AOU5XV'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=N824AOU5XV" class="external text external">N824AOU5XV</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D05394  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D05394'" tppabs="https://www.kegg.jp/entry/D05394" class="external text external">D05394</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201515  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201515'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201515" class="external text external">ChEMBL1201515</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>990</sub><span>H</span><sub>1532</sub><span>N</span><sub>262</sub><span>O</span><sub>300</sub><span>S</span><sub>7</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td>22129.0 g/mol (unpegylated)<span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464197586&page2=Pegvisomant  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464197586&page2=Pegvisomant'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=464197586&page2=Pegvisomant" class="external text external">(verify)</a></span></span></td></tr></tbody></table>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Discovery">Discovery</h2></summary>
    
<p>Pegvisomant was discovered at Ohio University in 1987 by Distinguished Professor John Kopchick and graduate student Wen Chen at the Edison Biotechnology Institute.  After completing clinical trials, it was approved for the treatment of acromegaly by the FDA in 2003 and marketed by Pfizer.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Structure">Structure</h2></summary>
    
<p>Pegvisomant is a protein containing 191 amino acid residues to which several <a href="Polyethylene_glycol.htm" tppabs="https://ptable.com/wiki/compounds/A/Polyethylene_glycol" title="Polyethylene glycol">polyethylene glycol</a> polymers have been covalently bound in order to slow clearance from the blood.<span class="mw-ref" id="cite_ref-ema_3-1"><a href="#cite_note-ema-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> The protein is a modified version of <a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">human growth hormone</a> designed to bind to and block the growth hormone receptor. It is manufactured using genetically modified <i>E. coli</i> bacteria.<span class="mw-ref" id="cite_ref-ema_3-2"><a href="#cite_note-ema-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Pegvisomant blocks the action of growth hormone on the growth hormone receptor to reduce the production of IGF-1. [5] [6] IGF-1 is responsible for most of the symptoms of acromegaly, and the normalization of its levels can control the symptoms.[<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span><span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> IGF-1 is responsible for most of the symptoms of acromegaly, and normalising its levels may control the symptoms.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>Long-term treatment studies with pegvisomant as a monotherapy have shown it to be safe,<span class="mw-ref" id="cite_ref-ReferenceA_2-1"><a href="#cite_note-ReferenceA-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> and to date it is the most effective treatment of acromegaly as both a monotherapy and in combination with somatostatin analogues.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>Side effects of pegvisomant include reactions at the injection site, swelling of the limbs, chest pain, hypoglycemia, nausea and hepatitis.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span></p>

<p>.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Other_potential_uses">Other potential uses</h2></summary>
    
<p>Recent studies have shown the potential of using pegvisomant as an anti-tumor treatment for certain types of cancers, in combination with other treatments.</p>

<p><span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li>PEGylation</li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-Schreiber-1"> <span id="mw-reference-text-cite_note-Schreiber-1" class="mw-reference-text"><cite id="CITEREFSchreiberBuchfelderDrosteForssmann2007" class="citation journal cs1">Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ (January 2007). <a href="javascript:if(confirm('https://doi.org/10.1530/eje.1.02312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530/eje.1.02312'" tppabs="https://doi.org/10.1530/eje.1.02312" class="external text external">"Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study"</a>. <i>European Journal of Endocrinology</i>. <b>156</b> (1): 75–82. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1530%2Feje.1.02312  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2Feje.1.02312'" tppabs="https://doi.org/10.1530%2Feje.1.02312" class="external text external">10.1530/eje.1.02312</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17218728  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17218728'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17218728" class="external text external">17218728</a>.</cite></span></li><li id="cite_note-ReferenceA-2"> <span id="mw-reference-text-cite_note-ReferenceA-2" class="mw-reference-text"><cite id="CITEREFFredaGordonKelepourisJonsson2015" class="citation journal cs1">Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (March 2015). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618502'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618502" class="external text external">"Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY"</a>. <i>Endocrine Practice</i>. <b>21</b> (3): 264–74. doi:<a href="javascript:if(confirm('https://doi.org/10.4158%2FEP14330.OR  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.4158%2FEP14330.OR'" tppabs="https://doi.org/10.4158%2FEP14330.OR" class="external text external">10.4158/EP14330.OR</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618502'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618502" class="external text external">4618502</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25370326  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25370326'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25370326" class="external text external">25370326</a>.</cite></span></li><li id="cite_note-ema-3"> <span id="mw-reference-text-cite_note-ema-3" class="mw-reference-text"><cite class="citation report cs1"><a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000409/WC500054625.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000409/WC500054625.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000409/WC500054625.pdf" class="external text external">Scientific Discussion of Somavert</a> <span class="cs1-format">(PDF)</span> (Report). European Medicines Agency. 2004.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.ohio.edu/research/communications/royaltymonetization.cfm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ohio.edu/research/communications/royaltymonetization.cfm'" tppabs="https://www.ohio.edu/research/communications/royaltymonetization.cfm" class="external text external">"Ohio University, inventors to receive up to $52 million from drug license transactions"</a>. Ohio University. Feb 15, 2011.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFKopchick2003" class="citation journal cs1">Kopchick JJ (April 2003). <a href="javascript:if(confirm('https://doi.org/10.1530/eje.0.148s021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530/eje.0.148s021'" tppabs="https://doi.org/10.1530/eje.0.148s021" class="external text external">"Discovery and mechanism of action of pegvisomant"</a>. <i>European Journal of Endocrinology</i>. 148 Suppl 2: S21-5. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1530%2Feje.0.148s021  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2Feje.0.148s021'" tppabs="https://doi.org/10.1530%2Feje.0.148s021" class="external text external">10.1530/eje.0.148s021</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12670297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12670297'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12670297" class="external text external">12670297</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite id="CITEREFBerrymanPalmerGosneySwaminathan2007" class="citation journal cs1">Berryman DE, Palmer AJ, Gosney ES, Swaminathan S, DeSantis D, Kopchick JJ (2007). "Discovery and uses of pegvisomant: a growth hormone antagonist". <i>Endokrynologia Polska</i>. <b>58</b> (4): 322–9. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18058724  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18058724'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18058724" class="external text external">18058724</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation report cs1"><a href="javascript:if(confirm('http://www.cadth.ca/media/cdr/complete/cdr_complete_Somavert_%20August2_2006.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cadth.ca/media/cdr/complete/cdr_complete_Somavert_%20August2_2006.pdf'" tppabs="http://www.cadth.ca/media/cdr/complete/cdr_complete_Somavert_%20August2_2006.pdf" class="external text external">CEDAC Final REcommendation on Reconsideration and Reasons for Recommendation: Pegvisomant (Somavert - Pfizer Canada Inc.)</a> <span class="cs1-format">(PDF)</span> (Report). Canadian Agency for Drugs and Technologies in Health. August 2, 2006.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite id="CITEREFNeggersMuhammadvan_der_Lely2015" class="citation journal cs1">Neggers SJ, Muhammad A, van der Lely AJ (2015). "Pegvisomant Treatment in Acromegaly". <i>Neuroendocrinology</i>. <b>103</b> (1): 59–65. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000381644  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000381644'" tppabs="https://doi.org/10.1159%2F000381644" class="external text external">10.1159/000381644</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25792221  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25792221'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25792221" class="external text external">25792221</a>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFFeenstravan_Akende_HerderFeelders2006" class="citation journal cs1">Feenstra J, van Aken MO, de Herder WW, Feelders RA, van der Lely AJ (June 2006). <a href="javascript:if(confirm('https://doi.org/10.1530/eje.1.02160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530/eje.1.02160'" tppabs="https://doi.org/10.1530/eje.1.02160" class="external text external">"Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant"</a>. <i>European Journal of Endocrinology</i>. <b>154</b> (6): 805–6. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1530%2Feje.1.02160  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1530%2Feje.1.02160'" tppabs="https://doi.org/10.1530%2Feje.1.02160" class="external text external">10.1530/eje.1.02160</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16728538  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16728538'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16728538" class="external text external">16728538</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFMooreAdiConnockBayliss2009" class="citation journal cs1">Moore DJ, Adi Y, Connock MJ, Bayliss S (October 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727" class="external text external">"Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation"</a>. <i>BMC Endocrine Disorders</i>. <b>9</b>: 20. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1472-6823-9-20  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1472-6823-9-20'" tppabs="https://doi.org/10.1186%2F1472-6823-9-20" class="external text external">10.1186/1472-6823-9-20</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768727" class="external text external">2768727</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19814797  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19814797'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19814797" class="external text external">19814797</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite id="CITEREFEvansJamiesonLiuWilson2016" class="citation journal cs1">Evans A, Jamieson SM, Liu DX, Wilson WR, Perry JK (August 2016). "Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model". <i>Cancer Letters</i>. <b>379</b> (1): 117–23. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.canlet.2016.05.031  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.canlet.2016.05.031'" tppabs="https://doi.org/10.1016%2Fj.canlet.2016.05.031" class="external text external">10.1016/j.canlet.2016.05.031</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/27241667  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/27241667'" tppabs="https://pubmed.ncbi.nlm.nih.gov/27241667" class="external text external">27241667</a>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFDivisovaKuiatseLazardWeiss2006" class="citation journal cs1">Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL,  et al. (August 2006). "The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth". <i>Breast Cancer Research and Treatment</i>. <b>98</b> (3): 315–27. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10549-006-9168-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10549-006-9168-1'" tppabs="https://doi.org/10.1007%2Fs10549-006-9168-1" class="external text external">10.1007/s10549-006-9168-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16541323  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16541323'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16541323" class="external text external">16541323</a>.</cite></span></li></ol></div>

<div role="navigation" class="navbox" aria-labelledby="GH/IGF-1_axis_signaling_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="GH/IGF-1_axis_signaling_modulators" style="font-size:114%;margin:0 4em"><abbr>GH</abbr>/<abbr>IGF-1</abbr> axis signaling modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GH</abbr><br><small>(somatotropin)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">Albusomatropin</span></li>
<li>Bovine somatotropin</li>
<li><span class="new">Efpegsomatropin</span></li>
<li><span class="new">Eftansomatropin alfa</span></li>
<li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Human placental lactogen</li>
<li>Placental growth hormone (growth hormone variant)</li>
<li><span class="new">Somagrebove</span></li>
<li><span class="new">Somapacitan</span></li>
<li><span class="new">Somatosalm</span></li>
<li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Somatotropin" title="Somatotropin" class="mw-redirect">Somatotropin</a></li>
<li><span class="new">Somatropin pegol</span></li>
<li>Somatrem</li>
<li><span class="new">Sometribove</span></li>
<li><span class="new">Somatrogon (MOD-4023; hGH-CTP)</span></li>
<li><span class="new">Somavaratan</span></li>
<li><span class="new">Somavubove</span></li>
<li><span class="new">Somidobove</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">G120K-hGH</span></li>
<li><a href="Pegvisomant.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegvisomant" title="Pegvisomant">Pegvisomant</a></li></ul>

<ul><li><i>Antisense oligonucleotides:</i> <span class="new">Atesidorsen</span></li></ul>

<ul><li><i>Binding proteins:</i> <abbr>GHBP</abbr></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GHIH</abbr><br><small>(somatostatin)</small></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <span class="new">BIM-23052</span></li>
<li><span class="new">CH-275</span></li>
<li><span class="new">Cortistatin-14</span></li>
<li><span class="new">Depreotide</span></li>
<li>Edotreotide</li>
<li><span class="new">Ilatreotide</span></li>
<li><span class="new">L-803,087</span></li>
<li><span class="new">L-817,818</span></li>
<li>Lanreotide</li>
<li><span class="new">NNC 26-9100</span></li>
<li>Octreotate</li>
<li><a href="Octreotide.htm" tppabs="https://ptable.com/wiki/compounds/A/Octreotide" title="Octreotide">Octreotide</a></li>
<li>Pasireotide</li>
<li><span class="new">Pentetreotide</span></li>
<li><span class="new">RC-160</span></li>
<li><span class="new">Seglitide</span></li>
<li>Somatostatin (GHIH)</li>
<li><span class="new">Somatostatin (1-28)</span></li>
<li><span class="new">SRIF-14</span></li>
<li><span class="new">SRIF-28</span></li>
<li><span class="new">TT-232</span></li>
<li><a href="Vapreotide.htm" tppabs="https://ptable.com/wiki/compounds/A/Vapreotide" title="Vapreotide">Vapreotide</a></li>
<li><span class="new">Veldoreotide</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">BIM-23056</span></li>
<li><span class="new">Cyclosomatostatin</span></li>
<li><span class="new">CYN-154806</span></li>
<li><span class="new">Satoreotide</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GHRH</abbr><br><small>(somatocrinin)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <i>Peptide:</i> <span class="new">ALRN-5281</span></li>
<li>CJC-1295</li>
<li><span class="new">Dumorelin</span></li>
<li>GHRH</li>
<li>Modified GRF (1-29)</li>
<li><span class="new">Rismorelin</span></li>
<li><a href="Sermorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Sermorelin" title="Sermorelin">Sermorelin</a></li>
<li>Somatorelin</li>
<li>Tesamorelin</li></ul>

<ul><li><i>Antagonists:</i> <span class="new">MZ-5-156</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GHS</abbr><br><small>(ghrelin)</small></th><td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Agonists:</i> <i>Peptide:</i> <span class="new">Alexamorelin</span></li>
<li><span class="new">Cortistatin-14</span></li>
<li><span class="new">EP-51216</span></li>
<li>Examorelin (hexarelin)</li>
<li>Ghrelin</li>
<li><span class="new">GHRP-1</span></li>
<li><span class="new">GHRP-3</span></li>
<li><span class="new">GHRP-4</span></li>
<li><span class="new">GHRP-5</span></li>
<li>GHRP-6</li>
<li>Ipamorelin</li>
<li>Lenomorelin</li>
<li><span class="new">Livoletide</span></li>
<li><span class="new">LY-444711</span></li>
<li>Pralmorelin (GHRP-2)</li>
<li>Relamorelin</li>
<li>Tabimorelin</li>
<li>Ulimorelin; <i>Non-peptide:</i> <a href="Adenosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Adenosine" title="Adenosine">Adenosine</a></li>
<li>Anamorelin</li>
<li>Capromorelin</li>
<li><span class="new">CP-464709</span></li>
<li>Ibutamoren (MK-677)</li>
<li><span class="new">L-692,585</span></li>
<li>Macimorelin</li>
<li>SM-130686; <i>Unsorted:</i> <span class="new">LY-426410</span></li>
<li><span class="new">LY-444711</span></li></ul>

<ul><li><i>Antagonists:</i> <span class="new">A-778193</span></li>
<li><span class="new">Cortistatin-8</span></li>
<li><span class="new">(<small>D</small>-Lys³)-GHRP-6</span></li>
<li><span class="new">JMV2959</span></li>
<li><span class="new">YIL-781</span></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>IGF-1</abbr><br><small>(somatomedin)</small></th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>See here instead.</li></ul>
</div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<ul><li><i><b>See also:</b> Receptor/signaling modulators • Signaling peptide/protein receptor modulators</i></li></ul>
</div></td></tr></tbody></table></div>


<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-07-21" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Pegvisomant&oldid=968811388  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Pegvisomant&oldid=968811388'" tppabs="https://en.wikipedia.org/wiki/?title=Pegvisomant&oldid=968811388">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>